Since the US regulatory and litigation pathway for biosimilars was signed into law in March 2010, the FDA has approved 28 biosimilar products, including 16 drugs with indications for patients with cancer.
Matthew Gavidia
Advertisement
Articles by Matthew Gavidia
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
First-Line Niraparib Maintenance Yields Longer PFS in HRD-Positive vs HRD-Negative Optimally Debulked Ovarian Cancer
2
Dr Traina on Integrating T-DXd and Biomarkers Into Early-Stage HER2-Positive Breast Cancer Care
3
LITESPARK-022 PRO Data Further Support Adjuvant Belzutifan Plus Pembrolizumab in ccRCC
4
Dr Borgen on Matching Treatment to HER2 Biology in Early-Stage HER2-Positive Breast Cancer
5